Members
Advisory Committee
Derek Adams
Chief Executive Officer
Stellular Bio
Previously, Derek has served as chief technology and manufacturing officer at bluebird bio. SVP of CMC at Evelo Bioscience, and VP Technical & Strategic Product Development at Alexion Pharmaceuticals.
Prior to joining bluebird, Derek was the senior vice president of CMC at Evelo Biosciences. At Evelo, Derek established the initial process development function and supply chain for clinical studies and drove strategy for product development. Prior to his time at Evelo, he served as vice president of technical and Strategic Product Development at Alexion Pharmaceuticals, where his responsibilities included developing and supporting all manufacturing processes globally as well as global clinical supply chain. Derek holds a Ph.D. in Chemical Engineering from the University of Minnesota and a B.S. in Chemical Engineering with High Distinction from Worcester Polytechnic Institute (WPI).
Jean Bender
Vice President Pharmaceutical Sciences & Technology
Visterra
Jean Bender leads Visterra’s Pharmaceutical Sciences department, responsible for development, technology transfer and manufacturing, clinical supply and CMC sections of regulatory submissions. Prior to Visterra, Jean was Senior Director, BioProcess Engineering at Medimmune. She has authored more than 15 publications and presentations and holds a patent for preparing highly concentrated antibodies by ultrafiltration. Jean received her MS in Chemical Engineering from the University of California, Berkeley and her BS in Chemical Engineering from Lehigh University. Jean has been on Pall’s Scientific Advisory Board and serves on the Recovery of Biological Products Board and on the Chemical Engineering Advisory Board for Lehigh University. Jean is active in the American Chemical Society and the BioInnovation Group (BIG).
Susan Abu-Absi
Chief Technology Officer
2seventy bio
Susan Abu-Absi is Chief Technology & Manufacturing Officer at 2seventy bio, an oncology cell therapy company. She leads the Technical Development & Operations organization comprised of supply chain, internal and external manufacturing, CMC strategy, and process and analytical development. Previously, she led the oncology manufacturing organization at bluebird bio, having joined in 2017 as Vice President of Process and Analytical Development. Prior to joining bluebird, she spent more than ten years in the Global Product Development & Supply organization at Bristol Myers Squibb supporting clinical and commercial biologics drug substance manufacturing. Before BMS, Susan was a member of the Process Sciences organization at Bayer Healthcare in Berkeley, CA. Susan earned a Ph.D. in Chemical Engineering from the University of Minnesota, and a B.S. in Chemical Engineering, Summa Cum Laude with Honors, from the University of Toledo.
Gregg Nyberg
Chief Technology Officer
Landmark Bio
Gregg Nyberg is a biopharmaceutical executive with twenty-five years of experience in process development, clinical manufacturing, technology transfer and commercialization. He is currently Chief Technology Officer at Landmark Bio, where he is responsible for translational research, process and analytical development, facilities and engineering, digital integration and clinical manufacturing for advanced therapies including cell and gene therapy. Prior to joining Landmark, Gregg served in multiple leadership roles at Merck, Amgen and Wyeth BioPharma/Genetics Institute. Most recently, Gregg was Head of Biologics Process Research & Development at Merck, where he was responsible for discovery interface, process development and clinical manufacturing for Merck’s biologics pipeline. Gregg received his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.
Jorg Thommes
Executive Vice President Pharmaceutical Sciences & Operations
Repertoire Immune Medicines
Executive Members
Firoz Antia
Head of Oligonucleotide Development
Biogen
Engin Ayturk
Senior Director, CMC BioConjugation Process Development & Manufacturing
Exelixis
John Batal
Manager of Engineering
Nitto Denko Avecia
Huanchun Cui
Executive Director
Resilience
David Fritsch
Biotechnology Operations Consultant
Fritsch Consulting, LLC
Marion Glenn
Head of Technology
Resilience
Neal Gordon
Biologics Development, New Company Creation/Operations
Independent Consultant
Kathryn Golden
SVP Technical Operations & Cell Manufacturing
bit.bio
Dmitry Gumerov
Director Pharmaceutical Sciences & Technology
Visterra
Stephen Hamilton
Chief Technical Officer
Wheeler Bio
Canping Jiang
Senior Director, Biologics Strategy and PMO
Thermo Fisher Scientific
Dr. Anne Kantardjieff
Vice President Manufacturing
BlueBird Bio
Michael Laska
Senior Vice President, CMC Technical Development & Manufacturing
Flagship Labs85
Katherine Leitch
Vice President Global Technical Operations
Seres Therapeutics
Carrie Mason
Associate Director Biologics R&D PAT/Automation
Lonza
Michael Mietzner
Senior Vice President – New England
Agile GxP Advisors
Greg Papastoitsis
EVP of Process & Manufacturing Sciences
Ankyra Therapeutics
Tom Ransohoff
Principal
RTI Consulting
Joseph Shultz
Vice President & Head of Technical Development
Resilience
Peter Wojciechowski
CMC Knowledge Management
Moderna
Sarah Yuan
Chief Technical Operations Officer
Sigilon Therapeutics
Chun Zhang
Chief Technology & Quality Officer
Evelo Biosciences